Morgan Stanley’s Biogen BIIB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $398M | Sell |
2,170,940
-154,073
| -7% | -$28.4M | 0.02% | 624 |
|
|
2025
Q4 | $409M | Buy |
2,325,013
+73,478
| +3% | +$12M | 0.02% | 610 |
|
|
2025
Q3 | $315M | Buy |
2,251,535
+295,325
| +15% | +$39.9M | 0.02% | 700 |
|
|
2025
Q2 | $246M | Sell |
1,956,210
-34,458
| -2% | -$4.29M | 0.02% | 772 |
|
|
2025
Q1 | $272M | Buy |
1,990,668
+208,312
| +12% | +$29.8M | 0.02% | 699 |
|
|
2024
Q4 | $273M | Sell |
1,782,356
-104,890
| -6% | -$17.7M | 0.02% | 701 |
|
|
2024
Q3 | $366M | Buy |
1,887,246
+280,738
| +17% | +$58.7M | 0.03% | 585 |
|
|
2024
Q2 | $372M | Sell |
1,606,508
-94,875
| -6% | -$20.6M | 0.03% | 555 |
|
|
2024
Q1 | $367M | Sell |
1,701,383
-1,454,171
| -46% | -$341M | 0.03% | 556 |
|
|
2023
Q4 | $817M | Buy |
3,155,554
+1,662,441
| +111% | +$408M | 0.04% | 475 |
|
|
2023
Q3 | $384M | Buy |
1,493,113
+61,814
| +4% | +$16.5M | 0.04% | 455 |
|
|
2023
Q2 | $408M | Buy |
1,431,299
+125,448
| +10% | +$37.3M | 0.04% | 431 |
|
|
2023
Q1 | $363M | Sell |
1,305,851
-116,965
| -8% | -$32.4M | 0.04% | 468 |
|
|
2022
Q4 | $394M | Buy |
1,422,816
+180,012
| +14% | +$50.8M | 0.04% | 418 |
|
|
2022
Q3 | $332M | Sell |
1,242,804
-134,131
| -10% | -$28.5M | 0.05% | 402 |
|
|
2022
Q2 | $281M | Buy |
1,376,935
+421,106
| +44% | +$86.1M | 0.04% | 473 |
|
|
2022
Q1 | $201M | Buy |
955,829
+175,349
| +22% | +$38.1M | 0.03% | 529 |
|
|
2021
Q4 | $187M | Buy |
780,480
+26,765
| +4% | +$6.88M | 0.02% | 597 |
|
|
2021
Q3 | $213M | Buy |
753,715
+51,540
| +7% | +$16.9M | 0.03% | 509 |
|
|
2021
Q2 | $243M | Buy |
702,175
+84,388
| +14% | +$25.6M | 0.03% | 477 |
|
|
2021
Q1 | $173M | Sell |
617,787
-159,716
| -21% | -$43.1M | 0.03% | 533 |
|
|
2020
Q4 | $190M | Buy |
777,503
+84,106
| +12% | +$21.7M | 0.03% | 490 |
|
|
2020
Q3 | $197M | Buy |
693,397
+316,681
| +84% | +$88.3M | 0.04% | 390 |
|
|
2020
Q2 | $101M | Buy |
376,716
+4,803
| +1% | +$1.44M | 0.02% | 554 |
|
|
2020
Q1 | $118M | Sell |
371,913
-54,303
| -13% | -$16.5M | 0.03% | 449 |
|
|
2019
Q4 | $126M | Sell |
426,216
-235,934
| -36% | -$65.5M | 0.03% | 518 |
|
|
2019
Q3 | $154M | Buy |
662,150
+163,935
| +33% | +$38.2M | 0.04% | 418 |
|
|
2019
Q2 | $117M | Sell |
498,215
-465,448
| -48% | -$107M | 0.03% | 514 |
|
|
2019
Q1 | $228M | Sell |
963,663
-49,083
| -5% | -$15.5M | 0.06% | 300 |
|
|
2018
Q4 | $305M | Buy |
1,012,746
+36,241
| +4% | +$11.6M | 0.09% | 224 |
|
|
2018
Q3 | $345M | Sell |
976,505
-774,604
| -44% | -$267M | 0.09% | 233 |
|
|
2018
Q2 | $508M | Buy |
1,751,109
+664,096
| +61% | +$187M | 0.14% | 151 |
|
|
2018
Q1 | $298M | Sell |
1,087,013
-8,734
| -0.8% | -$2.71M | 0.08% | 246 |
|
|
2017
Q4 | $349M | Sell |
1,095,747
-2,203
| -0.2% | -$707K | 0.1% | 219 |
|
|
2017
Q3 | $344M | Buy |
1,097,950
+18,673
| +2% | +$5.53M | 0.1% | 206 |
|
|
2017
Q2 | $293M | Buy |
1,079,277
+115,497
| +12% | +$30.5M | 0.09% | 253 |
|
|
2017
Q1 | $264M | Sell |
963,780
-2,920
| -0.3% | -$826K | 0.08% | 260 |
|
|
2016
Q4 | $274M | Sell |
966,700
-49,494
| -5% | -$14.7M | 0.09% | 241 |
|
|
2016
Q3 | $318M | Buy |
1,016,194
+17,831
| +2% | +$5.28M | 0.11% | 198 |
|
|
2016
Q2 | $241M | Sell |
998,363
-79,069
| -7% | -$20.8M | 0.09% | 249 |
|
|
2016
Q1 | $280M | Sell |
1,077,432
-161,512
| -13% | -$42.7M | 0.11% | 207 |
|
|
2015
Q4 | $380M | Sell |
1,238,944
-87,470
| -7% | -$25.1M | 0.14% | 168 |
|
|
2015
Q3 | $387M | Buy |
1,326,414
+29,764
| +2% | +$9.83M | 0.14% | 162 |
|
|
2015
Q2 | $524M | Sell |
1,296,650
-21,265
| -2% | -$8.53M | 0.18% | 134 |
|
|
2015
Q1 | $556M | Sell |
1,317,915
-250,581
| -16% | -$98.8M | 0.2% | 119 |
|
|
2014
Q4 | $532M | Buy |
1,568,496
+309,905
| +25% | +$100M | 0.19% | 119 |
|
|
2014
Q3 | $416M | Buy |
1,258,591
+321,800
| +34% | +$106M | 0.16% | 145 |
|
|
2014
Q2 | $295M | Buy |
936,791
+138,529
| +17% | +$41.7M | 0.12% | 205 |
|
|
2014
Q1 | $244M | Sell |
798,262
-3,641
| -0.5% | -$1.16M | 0.1% | 230 |
|
|
2013
Q4 | $224M | Buy |
801,903
+390,349
| +95% | +$101M | 0.1% | 237 |
|
|
2013
Q3 | $99.1M | Sell |
411,554
-168,202
| -29% | -$37.6M | 0.05% | 417 |
|
|
2013
Q2 | $125M | Buy |
+579,756
| New | +$124M | 0.06% | 346 |
|
Other funds holding BIIB
VCM
VPM
Morgan Stanley's BIIB Position: Q1 2026 in Review
Morgan Stanley reduced its Biogen (BIIB) stake by 6.6% in Q1 2026, selling an estimated $28.4M and leaving 2,170,940 shares worth $398M. The position accounts for 0.02% of the portfolio, ranked #624.
Morgan Stanley first reported a position in BIIB in Q2 2013 and has held it in 52 quarters since. The position peaked at $817M in Q4 2023. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.
- Morgan Stanley held 2,170,940 shares of Biogen worth $398M as of Q1 2026.
- Morgan Stanley sold 154,073 Biogen shares in Q1 2026, an estimated $28.4M.
- Biogen made up 0.02% of Morgan Stanley's portfolio in Q1 2026, its #624 holding.
- Morgan Stanley first reported a position in Biogen in Q2 2013 and has held it in 52 quarters since.
- Morgan Stanley's Biogen position peaked at $817M in Q4 2023.
- 1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.